Inventiva S.A. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Daix (france), long island city (new york, united states), april 3, 2024 – inventiva (euronext paris and nasdaq: iva) (the “company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“mash”), also known as non-alcoholic steatohepatitis (“nash”), and other diseases with significant unmet medical needs, today announced that it had filed its 2023 universal registration document for the year ended december 31, 2023, including the management report and the annual financial report, with the french “autoritÉ des marchÉs financiers” (“amf”) and its 2023 annual report on form 20-f for the year ended december 31, 2023 with the u...

Daix (france), long island city (new york, united states), march 28, 2024 – inventiva (euronext paris and nasdaq: iva) (the “company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“mash”), also known as non-alcoholic steatohepatitis (“nash”) and other diseases with significant unmet medical needs, today announced the nomination of andre turenne to its board of directors. mr. turenne's appointment will be submitted to the shareholders for ratification at the next general shareholder meeting.

Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022  cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposit at €9.0 million2 as of december 31, 2023, compared to €86.7 million, €1.0 million, and €0.7 million respectively, as of december 31, 2022 in september 2023, inventiva entered into an exclusive licensing agreement with hepalys to develop and commercialize lanifibranor in japan and south korea in january 2024, inventiva received the second tranche of €25 million under the eib loan agreement following its august 2023 financing of €35.7 million in gross proceeds, the upfront payment of $10 million from hepalys in october 2023 and milestone payments from cttq of $5 million in 2023 estimated cash runway until the beginning of the third quarter of 20243 positive results from the legend phase iia study combining lanifibranor with empagliflozin in patients with mash/nash and t2d announced in march 2024 last patient first visit of nativ3 phase iii clinical trial with lanifibranor targeted for first half 2024   daix (france), long island city (new york, united states), march 27, 2024 – inventiva (euronext paris and nasdaq: iva) (the “company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“mash”), also known as non-alcoholic steatohepatitis (“nash”), and other diseases with significant unmet medical needs, today reported its full-year results for 2023...

Daix (france), long island city (new york, united states), march 22, 2024 – inventiva (euronext paris and nasdaq: iva), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (mash), also known as non-alcoholic steatohepatitis (nash), and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the company's 2023 full-year financial results on thursday, march 28, 2024.

Daix (france), long island city (new york, united states), march 18, 2024 – inventiva (euronext paris and nasdaq: iva), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (mash), also known as non-alcoholic steatohepatitis (nash), and other diseases with significant unmet medical needs, today announces positive results of its interim analysis of the phase ii, proof-of-concept clinical trial, legend, evaluating lanifibranor in combination with empagliflozin in patients with mash/nash and poorly controlled type 2 diabetes (t2d).

Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH,  and other diseases with significant unmet medical needs, will hold an investor conference on Tuesday, March 19 , to share the results of the LEGEND Phase II trial, a placebo-controlled, study evaluating lanifibranor alone and in combination with the SGLT2 inhibitor empagliflozin in patients with MASH/NASH and type 2 diabetes (T2D).

IVA has robust data from a mid-stage NASH trial. They have an ongoing pivotal study running, to topline in H2 2025. They don't have enough cash to complete that trial.

Inventiva S.A. (NASDAQ:IVA ) 2022 Full Year Results Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Frédéric Cren – Chief Executive Officer Jean Volatier – Chief Financial Officer Michael Cooreman – Chief Medical Officer Conference Call Participants Seamus Fernandez – Guggenheim Securities Annabel Samimy – Stifel Ed Arce – H.C.

Inventiva S.A. (NASDAQ:IVA ) Q2 2022 Earnings Conference Call September 22, 2022 8:00 AM ET Company Participants Frédéric Cren - Co-Founder and CEO Pierre Broqua - Co-Founder and CSO Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial Officer Philip Duong - Head, Investment Conference Call Participants Ed Arce - H.C.

Inventiva S.A. Sponsored ADR (IVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Daix (France), Long Island City (New York, United States), June 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, announced today that it will host a webcast event focused on NASH with the participation of three Key Opinion Leaders (KOLs) on June 28, 2022, following the EASL International Liver Congress™ 2022.

Inventiva S.A. Sponsored ADR (IVA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.

The average of price targets set by Wall Street analysts indicates a potential upside of 166.4% in Inventiva S.A. Sponsored ADR (IVA).

Inventiva S.A. (IVA) CEO Frédéric Cren on Q4 2021 Results - Earnings Call Transcript

Inventiva (NASDAQ: IVA) announced the results of a clinical thorough QT/QTc study demonstrating the safety of lanifibranor on cardiac electrical activity. The assessment of lanifibranor on cardiac repolarization was conducted under FDA in Phase 1 double-blind clinical trial to be included in the marketing application package of lanifibranor for the treatment of NASH.